Guardant Health, Inc. (NASDAQ:GH - Get Free Report) shares were up 7.3% during trading on Wednesday after Canaccord Genuity Group raised their price target on the stock from $30.00 to $38.00. Canaccord Genuity Group currently has a buy rating on the stock. Guardant Health traded as high as $30.23 and last traded at $30.04. Approximately 1,585,702 shares changed hands during trading, a decline of 23% from the average daily volume of 2,051,672 shares. The stock had previously closed at $27.99.
Other equities analysts have also recently issued reports about the company. JPMorgan Chase & Co. reduced their target price on Guardant Health from $60.00 to $45.00 and set an "overweight" rating for the company in a research note on Friday, February 23rd. Stephens reissued an "overweight" rating and issued a $44.00 target price on shares of Guardant Health in a research report on Friday, May 24th. Guggenheim reaffirmed a "neutral" rating on shares of Guardant Health in a research report on Friday, April 5th. Piper Sandler lowered their price objective on Guardant Health from $40.00 to $30.00 and set an "overweight" rating for the company in a report on Monday, February 26th. Finally, The Goldman Sachs Group cut their target price on shares of Guardant Health from $32.00 to $28.00 and set a "buy" rating on the stock in a report on Monday, April 15th. Two investment analysts have rated the stock with a hold rating and twelve have assigned a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $36.91.
Read Our Latest Report on Guardant Health
Insiders Place Their Bets
In other news, insider Kumud Kalia purchased 2,187 shares of Guardant Health stock in a transaction that occurred on Monday, March 18th. The stock was acquired at an average price of $17.82 per share, for a total transaction of $38,972.34. Following the transaction, the insider now owns 12,722 shares in the company, valued at $226,706.04. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 5.50% of the company's stock.
Institutional Inflows and Outflows
Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Baillie Gifford & Co. acquired a new position in Guardant Health in the fourth quarter worth approximately $167,137,000. Capital International Investors raised its holdings in shares of Guardant Health by 36.7% during the 4th quarter. Capital International Investors now owns 4,001,803 shares of the company's stock valued at $108,249,000 after purchasing an additional 1,074,452 shares in the last quarter. Norges Bank acquired a new stake in shares of Guardant Health in the 4th quarter valued at $25,520,000. Cadian Capital Management LP acquired a new stake in shares of Guardant Health in the 4th quarter valued at $19,206,000. Finally, Mitsubishi UFJ Trust & Banking Corp acquired a new position in Guardant Health during the first quarter worth $8,300,000. 92.60% of the stock is owned by hedge funds and other institutional investors.
Guardant Health Trading Up 11.4 %
The company has a fifty day simple moving average of $20.85 and a two-hundred day simple moving average of $22.36. The company has a market capitalization of $3.82 billion, a P/E ratio of -7.76 and a beta of 1.15. The company has a debt-to-equity ratio of 16.70, a current ratio of 5.95 and a quick ratio of 5.66.
Guardant Health (NASDAQ:GH - Get Free Report) last announced its quarterly earnings results on Thursday, May 9th. The company reported ($0.94) EPS for the quarter, meeting the consensus estimate of ($0.94). Guardant Health had a negative return on equity of 246.47% and a negative net margin of 76.34%. The company had revenue of $168.49 million for the quarter, compared to the consensus estimate of $150.51 million. On average, analysts forecast that Guardant Health, Inc. will post -3.37 earnings per share for the current fiscal year.
Guardant Health Company Profile
(
Get Free Report)
Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.
Featured Stories
Before you consider Guardant Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Guardant Health wasn't on the list.
While Guardant Health currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.